You can view 5 more pages before signing in

This page is worth 0.05 CPD credits. CPD dashboard

This page is worth 0.05 CPD credits. Upgrade to Pro

You can view 5 more pages before signing in

This page is worth 0.05 CPD credits. CPD dashboard

This page is worth 0.05 CPD credits. Upgrade to Pro

EPHESUS trial (thrombosis prophylaxis)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

The EPHESUS trial aimed to determine whether the pentasaccharide fondaparinux was more effective than low-molecular-weight heparin at preventing deep venous thrombosis after elective hip replacement.

The multi-centre, double-blind trial enrolled 2309 consecutive patients, aged over 18 years, undergoing elective hip-replacement surgery. Patients were allocated to postoperative 2.5 mg s/c injections of fondaparinux vs. 40 mg s/c injections of enoxaparin daily.

Reference:

1) Lassen MR, Bauer KA, Eriksson BI, Turpie AG; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. (2002). Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359(9319):1715-20

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.